Immunotherapy has redefined the approach to cancer treatment by focusing on a fundamental principle: enhancing the immune system’s ability to recognize and eliminate tumor cells. Through this approach, treatments such as PD-1 inhibitors allow T cells that were previously “switched off” by the tumor to be reactivated, enabling a more effective response against cancer cells. However, despite these advances, a significant proportion of patients do not respond to treatment, and the reasons behind this variability are still not fully understood.
Recently, attention has begun to shift toward a factor that, until recently, went largely unnoticed: the gut microbiome. This community of microorganisms that resides in the intestine not only participates in digestion, but also plays a key role in regulating the immune system. The microbiome helps maintain immune balance, influencing how effectively the body can respond to diseases, including cancer. In this context, emerging evidence suggests that the composition of the microbiome could directly influence the success or failure of immunotherapy.
Within this framework, a recent study introduces an unexpected but important variable: artificial sweeteners. In particular, sucralose (widely used as a sugar substitute in “calorie-free” products) has been shown to alter the gut microbiome in ways that could compromise the effectiveness of anti-PD1 therapy. What for years was considered a compound with no significant biological impact is now beginning to emerge as a factor with real effects on the body, especially in the context of cancer treatment.
To explore this relationship, researchers used a mouse model responsive to anti-PD1 therapy, evaluating the effect of sucralose consumption during tumor development and treatment. The results were clear. Animals exposed to sucralose showed a significantly reduced response to immunotherapy compared to those that were not, demonstrating a decreased ability of the immune system to control tumor growth.
To better understand the mechanism, the study focused on the gut microbiome. Disrupting the microbiota using antibiotics produced a similar reduction in treatment response as observed with sucralose. Furthermore, transferring the microbiome from sucralose-exposed mice to non-exposed mice through fecal transplantation reproduced the loss of treatment effectiveness.
The effects on T cells were particularly important. These cells are responsible for identifying and destroying abnormal cells, including tumor cells. However, when exposed to certain factors, they can become less effective. In this case, exposure to sucralose was associated with reduced cytokine production, decreased proliferation, and a diminished ability to eliminate cancer cells. In addition, T cells showed signs of exhaustion, a state in which they progressively lose their functional capacity.
Figure 1. Sucralose may alter the gut microbiome, leading to weakened T cell activity and reduced effectiveness of immunotherapy.
This point is especially relevant when considering how anti-PD1 immunotherapy works. Under normal conditions, some tumor cells use mechanisms such as the PD-1/PD-L1 interaction to send inhibitory signals to T cells, reducing their activity and allowing the tumor to evade immune attack. Anti-PD1 drugs block this signal, enabling T cells to reactivate and continue their function. However, if these cells are already weakened or exhausted due to external factors such as changes in the microbiome, the effectiveness of the treatment may be limited.
Although these findings largely come from preclinical models, the study also identified a correlation in melanoma patients: sucralose consumption was associated with a reduced response to immunotherapy. While this observation does not establish direct causality, it provides a clinically relevant signal that aligns with the experimental findings.
Taken together, these results challenge the traditional view that treatment response depends solely on tumor biology and pharmacological intervention. Instead, they suggest that everyday, potentially modifiable factors such as diet may influence therapeutic outcomes. This does not mean that artificial sweeteners directly cause treatment failure, nor that eliminating them guarantees a better response, but it does highlight the importance of considering the biological context in which these therapies operate.
Figure 2. Sucralose exposure is associated with reduced T cell function, including lower cytokine production, decreased proliferation, and diminished ability to eliminate cancer cells.
From a clinical perspective, these findings should be interpreted with caution, but also with openness. They point toward the need for a more integrative approach to cancer treatment—one that considers not only advanced therapies, but also the factors that may modulate the immune system. As research in this field continues to evolve, the microbiome and its interaction with everyday exposures such as diet may become a key component of personalized medicine.
Main reference:
Morder K, Wilfahrt D, Xie B, Davar D, Nieves-Rosado H, Prado D, et al. 1322 Too sweet to be true: sucralose ablates immunotherapy response through microbiome disruption. Journal for ImmunoTherapy of Cancer. 2023;11:. https://doi.org/10.1136/jitc-2023-SITC2023.1322
Other references:
Olivares-Hernández, A., González Del Portillo, E., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca-Sánchez, E., & Miramontes-González, J. P. (2023). Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review. Annals of translational medicine, 11(10), 354. https://doi.org/10.21037/atm-22-4218
Suez, J., Korem, T., Zeevi, D., Zilberman-Schapira, G., Thaiss, C. A., Maza, O., Israeli, D., Zmora, N., Gilad, S., Weinberger, A., Kuperman, Y., Harmelin, A., Kolodkin-Gal, I., Shapiro, H., Halpern, Z., Segal, E., & Elinav, E. (2014). Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature, 514(7521), 181–186. https://doi.org/10.1038/nature13793
Sonnenburg, E. D., Smits, S. A., Tikhonov, M., Higginbottom, S. K., Wingreen, N. S., & Sonnenburg, J. L. (2016). Diet-induced extinctions in the gut microbiota compound over generations. Nature, 529(7585), 212–215. https://doi.org/10.1038/nature16504
